Frazier Life Sciences Acquisition Corp. II’s Quiet Period Will End on November 23rd (NASDAQ:FLSC)

Frazier Life Sciences Acquisition Corp. II’s (NASDAQ:FLSC – Get Free Report) quiet period will expire on Monday, November 23rd. Frazier Life Sciences Acquisition Corp. II had issued 7,500,000 shares in its public offering on October 14th. The total size of the offering was $75,000,000 based on an initial share price of $10.00. During Frazier Life Sciences Acquisition Corp. II’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Frazier Life Sciences Acquisition Corp. II to a “hold” rating in a research note on Saturday, October 24th.

Check Out Our Latest Report on FLSC

Frazier Life Sciences Acquisition Corp. II Stock Performance

Shares of FLSC stock opened at $10.07 on Wednesday. Frazier Life Sciences Acquisition Corp. II has a 12-month low of $9.95 and a 12-month high of $10.63.

Insiders Place Their Bets

In other Frazier Life Sciences Acquisition Corp. II news, CEO Albert Cha bought 300,000 shares of Frazier Life Sciences Acquisition Corp. II stock in a transaction on Thursday, October 15th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $3,000,000.00. Following the completion of the acquisition, the chief executive officer owned 300,000 shares in the company, valued at approximately $3,000,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

About Frazier Life Sciences Acquisition Corp. II

(Get Free Report)

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to pursue a merger, asset acquisition, stock purchase, reorganization or similar business combination. Its stated focus is on businesses in the life sciences sector. As a SPAC, the company does not itself develop or sell medicines, medical devices or other products. Its role is to identify and combine with a target business, which would then operate as a public company. The company is associated with Frazier Life Sciences, the life sciences investment arm of Frazier Healthcare Partners.

Recommended Stories

Receive News & Ratings for Frazier Life Sciences Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frazier Life Sciences Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.